keyword
MENU ▼
Read by QxMD icon Read
search

Non small cell lung

keyword
https://www.readbyqxmd.com/read/29786107/e3-ubiquitin-ligase-hakai-regulates-cell-growth-and-invasion-and-increases-the-chemosensitivity-to-cisplatin-in-non%C3%A2-small%C3%A2-cell-lung-cancer-cells
#1
Zi Liu, Yuqing Wu, Zijian Tao, Liang Ma
Hakai was originally identified as an E3 ubiquitin ligase of the E‑cadherin complex implicated in cell adhesion and invasion. Recently, emerging evidence has strongly suggested that Hakai serves a pivotal role in the tumorigenesis of certain tumors. However, the role of Hakai in non‑small‑cell lung cancer (NSCLC) and its underlying molecular mechanism have not been clarified. In the present study, it was observed that Hakai was highly expressed in NSCLC cell lines compared with human normal bronchial epithelial cells, and transfection with Hakai small interfering RNA significantly inhibited the growth of A549 and NCI‑H460 NSCLC cells...
May 17, 2018: International Journal of Molecular Medicine
https://www.readbyqxmd.com/read/29785875/egfr-tkis-in-non-small-cell-lung-cancer-focus-on-clinical-pharmacology-and-mechanisms-of-resistance
#2
Stefano Fogli, Beatrice Polini, Marzia Del Re, Iacopo Petrini, Antonio Passaro, Stefania Crucitta, Eleonora Rofi, Romano Danesi
The clinical introduction of EGFR-TKIs within the oncologic armamentarium has changed the therapeutic landscape of non-small-cell lung cancer (NSCLC) creating widespread expectations both in patients and clinicians. However, several gaps in current understanding leave open important questions regarding the use of these drugs in clinical practice. For instance, there is uncertainty in regard to which EGFR-TKI should be given first in naive patients with EGFR-driven malignancies since different generations of drugs are available with different pharmacological profiles...
May 22, 2018: Pharmacogenomics
https://www.readbyqxmd.com/read/29785577/atezolizumab-a-review-in-previously-treated-advanced-non-small-cell-lung-cancer
#3
REVIEW
Hannah A Blair
Atezolizumab (TECENTRIQ™), an immune checkpoint inhibitor, is an immunoglobulin G1 monoclonal antibody that binds to programmed death ligand 1 (PD-L1) and blocks its interactions with programmed death 1 and B7.1 receptors. Atezolizumab is approved as monotherapy in several countries worldwide for the treatment of patients with advanced non-small cell lung cancer (NSCLC) who have previously received chemotherapy. Approval was based on its clinical benefit in this setting in the phase II POPLAR and phase III OAK trials...
May 21, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29785299/thoracoscopic-segmentectomy-hybrid-approach-for-clinical-stage-i-non-small-cell-lung-cancer
#4
Koyo Shirahashi, Hirotaka Yamamoto, Mitsuyoshi Matsumoto, Yusaku Miyamaoto, Hiroyasu Komuro, Kiyoshi Doi, Hisashi Iwata
Background: Recently, minimally invasive surgical approaches have been developed, typified by video-assisted thoracic surgery (VATS). A meticulous surgical procedure to prevent local recurrence is required during segmentectomy for clinical stage I non-small-cell primary lung cancer. In this article, we demonstrated the validity of hybrid VATS segmentectomy. Methods: Of these 125 patients, 62 (49.6%) underwent intensively radical segmentectomy (RS). The remaining 63 (50...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785296/division-of-the-intersegmental-plane-using-electrocautery-for-segmentectomy-in-clinical-stage-i-non-small-cell-lung-cancer
#5
Mitsuyoshi Matsumoto, Koyo Shirahashi, Hirotaka Yamamoto, Yusaku Miyamaoto, Hiroyasu Komuro, Kiyoshi Doi, Hisashi Iwata
Background: Division of intersegmental planes is one of the important practical issues for segmentectomy to obtain feasible outcomes without relapse for clinical stage I non-small cell lung cancer. Almost all surgeons perform this procedure using a stapler. However, division of intersegmental planes for segmentectomy can also be performed by electrocautery. In this article, we demonstrate the merits and drawbacks of division of the intersegmental plane by electrocautery for segmentectomy...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785295/uniportal-video-assisted-thoracoscopic-segmentectomy
#6
Luis Angel Hernandez-Arenas, Rushmi D Purmessur, Diego Gonzalez-Rivas
Uniportal video-assisted thoracoscopic surgery (VATS) segmentectomy is a technically more complex procedure than uniportal VATS lobectomy, since a detailed comprehension of the segmental anatomy is required. Anatomic sublobar resection can achieve outcomes equivalent to lobectomy in selected patients with stage IA non-small cell lung carcinoma (NSCLC). In this paper we describe our clinical experiences and introduce the technical details of uniportal VATS segmentectomy, including expertise advice ("tips and tricks") in patient selection, positioning and incisions and technical highlights of the most common types of segmentectomies...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785293/planning-and-marking-for-thoracoscopic-anatomical-segmentectomies
#7
Agathe Seguin-Givelet, Madalina Grigoroiu, Emmanuel Brian, Dominique Gossot
Although sublobar resection (SLR) for treating non-small cell lung carcinoma (NSCLC) is still controversial, thoracoscopic segmentectomy is rising. Performing it by closed chest surgery is complex as it means confirming the location of the lesion, identifying vascular and bronchial structures, preserving venous drainage of adjacent segments, severing the intersegmental plane and ensuring an oncological safety margin with no manual palpation and different landmarks. Accurate planning is mandatory. We discuss in this article the interest of 3D reconstruction and mapping technics to enhance safety and reliability of these procedures...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785288/t1a-lung-carcinoma-the-place-of-segmentectomy-in-the-treatment-array
#8
Sameer A Hirji, Scott J Swanson
Contemporary management of early stage non-small cell lung cancer (NSCLC) is evolving and can be attributed to a change in size and histology of lung cancer, advancements in imaging modalities, instrumentation and surgical techniques. The emergence of segmentectomy has further challenged the existing treatment landscape, with promising results. Despite limited widespread adoption, video-assisted thoracoscopic surgery (VATS) segmentectomy is a safe option in the treatment of patients with small stage I lung cancers, with excellent oncologic results and improved morbidity relative to open techniques...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785287/lymph-node-dissection-during-sublobar-resection-why-when-and-how
#9
REVIEW
Pascal-Alexandre Thomas
Appropriate lymph node (LN) assessment is a hallmark of surgical quality of curative intent operations for non-small cell lung cancer (NSCLC). Even in the era of extensive pre-treatment work-up including routine PET-scanning and brain imaging, and selective invasive LN evaluation, unexpected LN metastases are found at surgery in more than 10% of patients with a cT1aN0 tumor. Systematic lymphadenectomy minimizes the risk of leaving tumor-LN behind and thus the risk of an incomplete resection, and provides the most truthful pTNM, which is decisive in directing adjuvant chemotherapy...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785286/anatomical-variations-and-pitfalls-to-know-during-thoracoscopic-segmentectomies
#10
REVIEW
Dominique Gossot, Agathe Seguin-Givelet
The rate of sublobar resection (SLR) for early-stage non-small cell lung carcinoma (NSCLC) is increasing, mainly because of a growing rate of early-stage lung carcinomas and ground-glass opacities. More and more SLRs are now performed by a thoracoscopic, a video-assisted or a robotically-assisted approach. Although surgeons are performing pulmonary segmentectomies for years, they need a better understanding of anatomy when using a closed chest approach, because vision is more limited and they cannot stretch and expose the parenchyma and broncho-vascular elements...
April 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29785088/insight-into-resistance-mechanism-of-anaplastic-lymphoma-kinase-to-alectinib-and-jh-viii-157-02-caused-by-g1202r-solvent-front-mutation
#11
Han Wang, Yao Wang, Wentao Guo, Bin Du, Xiaobing Huang, Riping Wu, Baoyu Yang, Xiaoyan Lin, Yilan Wu
Background: Mutated anaplastic lymphoma kinase (ALK) drives the development of advanced non-small cell lung cancer (NSCLC). Most reported small-molecule inhibitors targeting the ALK domain do not display good inhibition of the G1202R solvent front mutation. The solvent front mutation was assumed to hinder drug binding. However, a different fact could be uncovered by the simulations reported in this study through a structural analog of alectinib (JH-VIII-157-02), which demonstrated potent effects against the G1202R mutation...
2018: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/29784736/targeted-therapy-for-patients-with-metastatic-non-small-cell-lung-cancer
#12
Karen L Reckamp
Molecular testing is recommended for initial diagnosis in patients with non-small cell lung cancer (NSCLC), according to the updated NCCN Guidelines, because targeted therapies are available that can improve patient outcomes. Targeted therapies are currently approved for EGFR mutations, ALK and ROS1 gene rearrangements, and BRAF mutations, with the list of emerging "actionable" targets growing. The 2018 NCCN Guidelines for NSCLC incorporate new therapies, including the EGFR tyrosine kinase inhibitor osimertinib and the ALK inhibitor alectinib, as first-line preferences...
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29784577/isolated-solitary-muscle-recurrence-of-early-stage-non-small-cell-lung-cancer-detected-by-18-f-fdg-pet-ct
#13
R Wang, C Chen, C Fan, M Su
No abstract text is available yet for this article.
May 19, 2018: Revista Española de Medicina Nuclear e Imagen Molecular
https://www.readbyqxmd.com/read/29784046/knockdown-of-annexin-a5-restores-gefitinib-sensitivity-by-promoting-g2-m-cell-cycle-arrest
#14
Jian Zhou, Meijia Chang, Jing Li, Tao Fang, Jie Hu, Chunxue Bai
BACKGROUND: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, including gefitinib, are first-line drugs against advanced non-small cell lung cancer with activating EGFR mutations. However, the development of resistance to such drugs is a major clinical challenge. METHODS: The role of annexin A5 in resistance to EGFR tyrosine kinase inhibitors was investigated by qPCR and western blot of relevant molecules, by CCK8 and EdU assay of cell proliferation and viability, by annexin V/propidium iodide assay of apoptosis and cell cycle distribution, by JC-1 assay of mitochondrial integrity, and by xenograft assay of tumorigenicity...
May 21, 2018: Respiratory Research
https://www.readbyqxmd.com/read/29783929/modulation-the-crosstalk-between-tumor-associated-macrophages-and-non-small-cell-lung-cancer-to-inhibit-tumor-migration-and-invasion-by-ginsenoside-rh2
#15
Honglin Li, Nan Huang, Weikang Zhu, Jianchun Wu, Xiaohui Yang, Wenjing Teng, Jianhui Tian, Zhihong Fang, Yingbin Luo, Min Chen, Yan Li
BACKGROUND: Tumor-associated macrophages (TAMs) play a critical role in modulating the tumor microenvironment and promote tumor metastases. Our studies have demonstrated that ginsenoside Rh2 (G-Rh2), a monomeric compound extracted from ginseng, is a promising anti-tumor agent in lung cancer cells. However, it remains unclear whetherG-Rh2 can modulate the differentiation of TAMs and its interaction with tumor microenvironment. In this study, we investigated how G-Rh2 regulates the phenotype of macrophages and affects the migration of non-small cell lung cancer (NSCLC) cells...
May 22, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29782924/emerging-biomarkers-for-immune-checkpoint-inhibition-in-lung-cancer
#16
REVIEW
George Cyriac, Leena Gandhi
Immune checkpoint inhibition with anti-PD-1 therapy has been notably successful in non-small cell lung cancer (NSCLC) and changed standard practice in multiple settings. However, despite some durable benefits seen, the majority of unselected patients with NSCLC fail to respond to checkpoint inhibitors. Patient selection is crucial and will become even more important in the development of combination therapies with immune checkpoint inhibitors. PD-L1 expression by immunohistochemistry (IHC) has emerged as the most commonly used clinical biomarker of response and overall tumor mutational burden (TMB) is being explored as a clinical biomarker...
May 18, 2018: Seminars in Cancer Biology
https://www.readbyqxmd.com/read/29782621/darpp-32-and-t-darpp-promote-non-small-cell-lung-cancer-growth-through-regulation-of-ikk%C3%AE-dependent-cell-migration
#17
Sk Kayum Alam, Matteo Astone, Ping Liu, Stephanie R Hall, Abbygail M Coyle, Erin N Dankert, Dane K Hoffman, Wei Zhang, Rui Kuang, Anja C Roden, Aaron S Mansfield, Luke H Hoeppner
Lung cancer is the leading cause of cancer-related death worldwide. Here we demonstrate that elevated expression of dopamine and cyclic adenosine monophosphate-regulated phosphoprotein, Mr 32000 (DARPP-32) and its truncated splice variant t-DARPP promote lung tumor growth, while abrogation of DARPP-32 expression in human non-small cell lung cancer (NSCLC) cells reduces tumor growth in orthotopic mouse models. We observe a novel physical interaction between DARPP-32 and inhibitory kappa B kinase-α (IKKα) that promotes NSCLC cell migration through non-canonical nuclear factor kappa-light-chain-enhancer of activated B cells 2 (NF-κB2) signaling...
2018: Communications biology
https://www.readbyqxmd.com/read/29782572/patient-related-outcomes-with-the-use-of-checkpoint-inhibitors-for-the-treatment-of-metastatic-non-small-cell-lung-cancer
#18
EDITORIAL
Jyoti Malhotra, Salma K Jabbour
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782567/quality-of-life-for-non-small-cell-lung-cancer-patients-in-the-age-of-immunotherapy
#19
EDITORIAL
Robert A Ramirez, Jonathan Lu, Katharine E H Thomas
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/29782566/post-operative-radiation-therapy-in-locally-advanced-non-small-cell-lung-cancer-and-the-impact-of-sequential-versus-concurrent-chemotherapy
#20
EDITORIAL
Mark R Waddle, Stephen Ko, Margaret M Johnson, Yanyan Lou, Robert C Miller, Anna C Harrell, Daniel M Trifiletti
No abstract text is available yet for this article.
April 2018: Translational Lung Cancer Research
keyword
keyword
32720
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"